FDA: “No evidence” second Pfizer COVID pill stops repeat symptoms, contradicting CEO

What they’re saying: "There is no evidence of benefit at this time for a longer course of treatment or repeating a treatment course of Paxlovid," John Farley, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said in a statement.

• Farley reiterated that Paxlovid "reduces the risk of hospitalization and death for patients with mild-to-moderate COVID-19 at high risk of disease progression" and is "expected to be effective against the Omicron variant."

Flashback: Bourla told Bloomberg that Paxlovid "reduces the viral load" but doesn’t always clear the coronavirus out of people’s systems.

• When that happens, people should take more of the drug, he said.

The bigger picture: Paxlovid, which received emergency use authorization from the FDA in December, has been shown to reduce hospitalization risks for vulnerable adults who are at high risk for severe COVID-19 symptoms.

• U.S. government researchers plan to research how and why COVID-19 patients relapse after taking the drug, Bloomberg reports.